241 related articles for article (PubMed ID: 33947337)
1. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
3. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.
Kondili LA; Gaeta GB; Brunetto MR; Di Leo A; Iannone A; Santantonio TA; Giammario A; Raimondo G; Filomia R; Coppola C; Amoruso DC; Blanc P; Del Pin B; Chemello L; Cavalletto L; Morisco F; Donnarumma L; Rumi MG; Gasbarrini A; Siciliano M; Massari M; Corsini R; Coco B; Madonia S; Cannizzaro M; Zignego AL; Monti M; Russo FP; Zanetto A; Persico M; Masarone M; Villa E; Bernabucci V; Taliani G; Biliotti E; Chessa L; Pasetto MC; Andreone P; Margotti M; Brancaccio G; Ieluzzi D; Borgia G; Zappulo E; Calvaruso V; Petta S; Falzano L; Quaranta MG; Weimer LE; Rosato S; Vella S; Giannini EG
PLoS One; 2017; 12(10):e0185728. PubMed ID: 28977040
[TBL] [Abstract][Full Text] [Related]
4. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
Berenguer J; Gil-Martin Á; Jarrin I; Moreno A; Dominguez L; Montes M; Aldámiz-Echevarría T; Téllez MJ; Santos I; Benitez L; Sanz J; Ryan P; Gaspar G; Alvarez B; Losa JE; Torres-Perea R; Barros C; Martin JVS; Arponen S; de Guzmán MT; Monsalvo R; Vegas A; Garcia-Benayas MT; Serrano R; Gotuzzo L; Menendez MA; Belda LM; Malmierca E; Calvo MJ; Cruz-Martos E; González-García JJ
Hepatology; 2018 Jul; 68(1):32-47. PubMed ID: 29377274
[TBL] [Abstract][Full Text] [Related]
5. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
Ridruejo E; Piñero F; Mendizabal M; Cheinquer H; Wolff FH; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Zuain MGV; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Silva M;
J Med Virol; 2020 Dec; 92(12):3545-3555. PubMed ID: 32749710
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ; Tran S; Huang CF; Hsu YC; Preda C; Toyoda H; Liu J; Jun DW; Landis C; Huang DQ; Gila A; Negoita L; Yasuda S; Tseng CH; Tsai PC; Uojima H; Nozaki A; Chuma M; Atsukawa M; Ishigami M; Itokawa N; Iio E; Lam CP; Watanabe T; Asai A; Yokohama K; Abe H; Enomoto M; Kawada N; Tamori A; Lee DH; Jun MJ; Do S; Vo DKH; Liu L; Li J; Ji F; Wang W; Li Y; Wang X; Guo F; Xu Q; Jing L; Ye Q; Pan H; Zhang J; Wen X; Wang Q; Ren H; Cai D; Shang J; Liu J; Lu C; Zang W; Li J; Niu J; Zhang M; Wu C; Huang R; Maeda M; Nakanishi A; Yeh ML; Chuang WL; Huang JF; Dai C; Ishikawa T; Takaguchi K; Senoh T; Trinh HN; Takahashi H; Eguchi Y; Quek SXZ; Haga H; Ogawa E; Wong G; Buti M; Fukunishi S; Ueno Y; Yuen MF; Tanaka Y; Lim SG; Cheung R; Yu ML; Nguyen MH
Hepatol Int; 2023 Oct; 17(5):1150-1161. PubMed ID: 37273170
[TBL] [Abstract][Full Text] [Related]
7. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
8. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C treatment initiation in HIV-HCV coinfected patients.
Cotte L; Pugliese P; Valantin MA; Cuzin L; Billaud E; Duvivier C; Naqvi A; Cheret A; Rey D; Pradat P; Poizot-Martin I;
BMC Infect Dis; 2016 Jul; 16():345. PubMed ID: 27450098
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
Taylor LE; Swan T; Matthews GV
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
[TBL] [Abstract][Full Text] [Related]
12. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
13. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras.
Jacob JS; Shaikh A; Goli K; Rich NE; Benhammou JN; Ahmed A; Kim D; Rana A; Goss JA; Naggie S; Lee TH; Kanwal F; Cholankeril G
Clin Infect Dis; 2023 Feb; 76(4):592-599. PubMed ID: 36221143
[TBL] [Abstract][Full Text] [Related]
14. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
[TBL] [Abstract][Full Text] [Related]
15. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
Gobran ST; Pagliuzza A; Khedr O; Fert A; Chomont N; Bruneau J; Klein MB; Ancuta P; Shoukry NH
J Virol; 2023 Dec; 97(12):e0110523. PubMed ID: 38051044
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
[TBL] [Abstract][Full Text] [Related]
17. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers.
Butt AA; Khan UA; Shaikh OS; McMahon D; Dorey-Stein Z; Tsevat J; Lo Re V
HIV Clin Trials; 2009; 10(1):25-32. PubMed ID: 19362993
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
Rockey DC; Friedman SL
Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
[TBL] [Abstract][Full Text] [Related]
19. Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.
Kondili LA; Zanetto A; Quaranta MG; Ferrigno L; Panetta V; Calvaruso V; Zignego AL; Brunetto MR; Raimondo G; Biliotti E; Ieluzzi D; Iannone A; Madonia S; Chemello L; Cavalletto L; Coppola C; Morisco F; Barbaro F; Licata A; Federico A; Cerini F; Persico M; Pompili M; Ciancio A; Piscaglia F; Chessa L; Giacometti A; Invernizzi P; Brancaccio G; Benedetti A; Baiocchi L; Gentile I; Coppola N; Nardone G; Craxì A; Russo FP;
United European Gastroenterol J; 2024 Apr; 12(3):352-363. PubMed ID: 38032175
[TBL] [Abstract][Full Text] [Related]
20. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
